微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 40.76% | -8.25% | -2.27% | 92/159 | -1.59% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 41.71% | -9.73% | 2.2% | 90/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 40.81% | -9.2% | -10.19% | 92/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 45.45% | -2.11% | 2.29% | 89/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 44.43% | -9.13% | -3.84% | 89/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 46.2% | -9.04% | 2.79% | 87/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 44.95% | -17.59% | -3.18% | 86/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 46.43% | -5.4% | -5.04% | 89/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 48.89% | 1.44% | -3.75% | 81/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 50.79% | 6.31% | -6.87% | 76/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 54.54% | 21.06% | 11.14% | 68/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 49.07% | 3.02% | 1.82% | 86/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 48.2% | -0.97% | 0.88% | 82/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 47.78% | -8.84% | 6.05% | 85/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 45.05% | -18.13% | -5.42% | 81/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 47.63% | 3.54% | -2.13% | 88/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 48.67% | 0.5% | -7.13% | 78/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 52.41% | 7.11% | -4.77% | 76/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 55.03% | 8.7% | 19.62% | 65/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 46.01% | -6.94% | -5% | 91/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 48.43% | 6.52% | -1.02% | 71/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 48.93% | 12.13% | -3.35% | 73/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 50.63% | 19.3% | 2.4% | 64/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 49.44% | -2.77% | 8.74% | 80/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 45.46% | -5.99% | 4.19% | 68/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 43.63% | -10.57% | 2.83% | 74/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 42.43% | -17.8% | -16.55% | 70/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 50.85% | 36.79% | 5.15% | 69/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 48.36% | 53.17% | -0.88% | 57/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 48.79% | 64.74% | -5.48% | 57/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 51.62% | 81.49% | 38.87% | 53/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 37.17% | 26.61% | 17.74% | 84/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 31.57% | 5.12% | 6.6% | 74/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 29.62% | 1.23% | 4.13% | 82/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 28.44% | 48.55% | -3.12% | 65/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 29.36% | 81.46% | -2.25% | 89/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 30.04% | 77.4% | 2.66% | 62/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 29.26% | 79.2% | 52.8% | 71/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 19.15% | 33.89% | 18.34% | 74/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 16.18% | 5.22% | -4.44% | 100/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 16.93% | 9.16% | 3.7% | 73/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 16.33% | 23.85% | 14.17% | 77/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 14.3% | 33.33% | -7% | 73/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |